Novo Nordisk

Aspect Biosystems Ltd. is a biotechnology company based in Vancouver, Canada, specializing in 3D bioprinting and tissue engineering. Founded in 2013, the company leverages proprietary microfluidic 3D bioprinting technology to develop bioprinted tissue therapeutics aimed at transforming disease treatment. By integrating therapeutic cells and materials science, Aspect Biosystems creates allogeneic cell-based tissue therapeutics that can replace or repair damaged organ functions. The company also provides a Lab-on-a-printer technology that allows precise control over biomaterial composition and structure during tissue fabrication. Its innovative platform supports the development of novel therapeutics and enhances understanding in fundamental biology and disease research, catering to pharmaceutical firms and academic institutions focused on respiratory diseases and regenerative medicine. Aspect Biosystems is actively collaborating with researchers and industry leaders to address significant challenges in the field of regenerative medicine.

Eikonizo Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, including Alzheimer's disease and amyotrophic lateral sclerosis. Founded in 2017 and based in Cambridge, Massachusetts, Eikonizo specializes in creating brain-penetrant small molecules, particularly selective histone deacetylase 6 inhibitors, which serve as disease-modifying treatments. The company employs advanced in vivo target engagement techniques to expedite the discovery of effective therapeutics. Through its research and development efforts, Eikonizo aims to transform the landscape of treatment options for patients suffering from debilitating neurological conditions.

Tanai Therapeutics develops novel therapeutics for people living with obesity and obesity-related complications.

Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, founded in 2016. The company specializes in developing non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is the leading cause of death in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a critical microRNA responsible for pathological changes in the heart resulting from stress or injury. Through its innovative approach, Cardior Pharmaceuticals seeks to address significant unmet medical needs in cardiovascular health.

Athlone is a provider of culture to art and heritage platform

Biocorp Production, established in 2004 and based in Issoire, France, specializes in the design, development, and manufacturing of medical devices and drug delivery systems. The company's portfolio includes smart caps for inhalers and pen injectors (Inspair, Mallya), motor-driven auto-injectors and pen injectors (Onejet, Datapen), and data collection devices (Injay). Additionally, Biocorp offers pharmaceutical devices such as safety devices (NEWGUARD) and reconstitution systems (BIOPASS), catering to various pharmaceutical needs.

Embark Biotech is an early-stage biotechnology company based in Copenhagen, Denmark, founded in 2017. The company focuses on identifying novel cell surface receptors that play a critical role in regulating calorie-burning in fat tissue, as well as the uptake of glucose and lipids. By developing receptors that stimulate energy expenditure without activating the sympathetic nervous system, Embark Biotech aims to address unmet clinical needs in the field of metabolic diseases.

Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, specializing in the development of peripherally-restricted CB1 receptor inverse agonists aimed at treating various metabolic and fibrotic disorders. Founded in 2015, the company focuses on creating innovative therapies for conditions such as Prader-Willi syndrome, diabetes, and complications related to obesity. Its pipeline includes treatments for diabetic kidney disease, non-alcoholic steatohepatitis, and progressive fibrosis, including interstitial lung disease. Inversago Pharma aims to improve patient outcomes by offering new therapeutic options that target the underlying mechanisms of these diseases.

ElevateBio, LLC is a holding company based in Cambridge, Massachusetts, founded in 2017. It focuses on developing cell and gene therapies for the treatment of cancer and viral infections. The company operates a portfolio of subsidiaries that aim to manufacture and commercialize innovative medicines. ElevateBio collaborates with leading scientists and inventors to create a robust portfolio of therapeutic solutions. Additionally, it has established a centralized facility designed to streamline the translation of cell and gene therapy research into viable medical products, ensuring that patients have access to treatments for severe diseases in a timely manner.

Aspect Biosystems Ltd. is a biotechnology company based in Vancouver, Canada, specializing in 3D bioprinting and tissue engineering. Founded in 2013, the company leverages proprietary microfluidic 3D bioprinting technology to develop bioprinted tissue therapeutics aimed at transforming disease treatment. By integrating therapeutic cells and materials science, Aspect Biosystems creates allogeneic cell-based tissue therapeutics that can replace or repair damaged organ functions. The company also provides a Lab-on-a-printer technology that allows precise control over biomaterial composition and structure during tissue fabrication. Its innovative platform supports the development of novel therapeutics and enhances understanding in fundamental biology and disease research, catering to pharmaceutical firms and academic institutions focused on respiratory diseases and regenerative medicine. Aspect Biosystems is actively collaborating with researchers and industry leaders to address significant challenges in the field of regenerative medicine.

The Sabi is a women-centric holistic beauty brand that specializes in all-natural, vegan skincare and herbal remedies. It caters to women throughout their hormonal journey, from conception to postpartum and menopause, addressing everyday hormonal imbalances. The company's products are free from endocrine disrupting chemicals (EDCs) and are backed by extensive testimonial data and continuous innovation. The Sabi empowers women to support their well-being through science-backed self-care rituals and expert support.

Amalgam Rx is a digital health company focused on creating custom digital therapies that integrate clinical and behavioral health interventions to enhance patient self-management for chronic diseases. The company aims to improve clinical and behavioral outcomes through its innovative platform, which offers features such as data insights, clinical decision support tools, and patient engagement resources. By partnering with life sciences companies, Amalgam accelerates the development and commercialization of clinically validated solutions tailored to address specific chronic conditions. Led by a team of experienced professionals from various fields, Amalgam Rx seeks to leverage technology to improve the lives of individuals living with chronic diseases.

Ventus Therapeutics is a biopharmaceutical company focused on discovering and developing innovative small molecule medicines that target the innate immune system. The company employs a structural immunology platform that provides deep insights into molecular structures and mechanisms, enabling precise targeting of the innate immune system. Ventus combines advanced protein engineering capabilities with cutting-edge rational and structure-based drug design tools to create therapeutics aimed at treating autoimmune diseases, inflammatory conditions, and cancer. The company is actively building a diverse pipeline of drug programs that address significant targets within the innate immune system, with the goal of advancing treatments for both acute and chronic inflammatory and immune-related diseases.

Forma Therapeutics, headquartered in Watertown, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for rare hematologic diseases and various cancers. The company is advancing several key product candidates, including FT-4202, currently in Phase 1 trials for sickle cell disease and other hemoglobinopathies, and FT-7051, targeting metastatic castration-resistant prostate cancer. Additionally, Forma is developing FT-2102, a selective small molecule designed to inhibit mutated IDH1 enzymes, which is being evaluated in Phase 2 trials for relapsed/refractory acute myeloid leukemia and in exploratory trials for glioma. Other candidates include FT-4101 and FT-8225, selective inhibitors of fatty acid synthase. The firm integrates advanced drug discovery technologies with deep oncology expertise to address challenging targets, contributing to a robust pipeline aimed at transforming patient outcomes in oncology.

Beta Bionics is a biotechnology company focused on developing advanced solutions for diabetes management. Its flagship product, the iLet Bionic Pancreas System, is an integrated device designed to alleviate the burden of diabetes care. This system encompasses a dual-chamber infusion pump that delivers insulin and glucagon with precision and accuracy, autonomously calculating and administering doses to help patients maintain optimal blood sugar levels. The iLet has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal, and it incorporates Zealand Pharma’s dasiglucagon, which is known for its stability in a ready-to-use aqueous solution. Through these innovations, Beta Bionics aims to improve the quality of life for individuals living with diabetes.

Dicerna Pharmaceuticals is a biopharmaceutical company that specializes in the discovery and development of RNA interference (RNAi)-based therapeutics. The company focuses on innovative treatments for rare inherited liver diseases, viral infections, chronic liver diseases, and cardiometabolic conditions. Utilizing its proprietary GalXC RNAi technology platform, Dicerna is advancing several key product candidates, including nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B, and programs targeting genetic liver diseases and cardiovascular conditions. Founded in 2007 and headquartered in Lexington, Massachusetts, Dicerna has established strategic collaborations with major pharmaceutical firms to enhance its research and development efforts.

Glooko is a company that develops a remote patient-monitoring platform specifically designed for individuals with diabetes. This platform integrates with various diabetes devices, fitness wearables, and activity trackers to capture and sync health data. It provides comprehensive reports and analytics aimed at promoting behavior change and improving health outcomes. By enhancing communication between patients and healthcare providers, Glooko facilitates better management of diabetes and supports remote monitoring efforts. The platform is accessible on both Android and iOS devices, allowing users to conveniently track their diabetes-related information on their smartphones.

Emisphere Technologies, Inc. is a pharmaceutical and drug delivery company based in Roseland, New Jersey, specializing in innovative oral formulations of therapeutic agents. The company is best known for its Eligen B12 Rx, a prescription medical food designed for individuals with vitamin B12 deficiencies, allowing for normalization of B12 levels without the need for injections. Emisphere is advancing its pipeline with several product candidates, including GLP-1, which is currently in Phase III clinical trials for the treatment of type 2 diabetes. The company also focuses on preclinical programs aimed at developing oral formulations for conditions related to diabetes, cardiovascular health, appetite suppression, and pain management. Emisphere collaborates with global pharmaceutical companies, including Novo Nordisk A/S, to leverage its proprietary Eligen Technology for creating oral versions of injectable bio-pharmaceuticals and other therapeutic agents. Founded in 1986, Emisphere Technologies has evolved from its original name, Clinical Technologies Associates, Inc., to its current identity, reflecting its commitment to advancing drug delivery solutions.

Sundew is a biotechnology company founded in 2018 and headquartered in Copenhagen. The company specializes in providing biological services designed to treat aquatic pests and diseases through innovative solutions. Utilizing precision fermentation, Sundew develops environmentally-friendly products aimed at addressing challenges in the aquaculture market, including the management of invasive species and ecological issues such as red tides. By focusing on unmet needs within this sector, Sundew enables its clients to create effective, cost-efficient solutions that are both climate-friendly and sustainable.

Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, that specializes in developing precision therapies for cardiovascular and renal diseases. Founded in 2014, the company focuses on researching and commercializing innovative treatments aimed at addressing chronic kidney disease, particularly in patients with atherosclerotic cardiovascular disease and inflammation, as well as conditions like high triglyceride-induced acute pancreatitis. Corvidia Therapeutics is recognized for its approach that targets specific biologic pathways, enabling healthcare providers to deliver more effective therapies to patients with unique sensitivities. As of July 2020, Corvidia operates as a subsidiary of Novo Nordisk A/S.

Beta Bionics is a biotechnology company focused on developing advanced solutions for diabetes management. Its flagship product, the iLet Bionic Pancreas System, is an integrated device designed to alleviate the burden of diabetes care. This system encompasses a dual-chamber infusion pump that delivers insulin and glucagon with precision and accuracy, autonomously calculating and administering doses to help patients maintain optimal blood sugar levels. The iLet has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal, and it incorporates Zealand Pharma’s dasiglucagon, which is known for its stability in a ready-to-use aqueous solution. Through these innovations, Beta Bionics aims to improve the quality of life for individuals living with diabetes.

Ziylo Ltd, founded in 2014 and based in Bristol, United Kingdom, specializes in the development of glucose binding molecules aimed at improving the lives of individuals with diabetes. The company's innovative approach is rooted in supramolecular chemistry and has led to the creation of a unique class of biomimetic glucose binding molecules (GBM). These molecules are integral to medical devices, such as Continuous Glucose Monitors (CGM), and therapeutic solutions like Glucose Responsive Insulins (GRI). Drawing on over 20 years of research from Professor Anthony Davis’ group at the University of Bristol, Ziylo's technology mimics nature's carbohydrate-binding molecules, known as lectins, to effectively bind glucose in blood. This pioneering work has garnered recognition in prestigious scientific journals, establishing Ziylo as a significant player in the field of diabetes management and treatment solutions. As of August 2018, Ziylo operates as a subsidiary of Novo Nordisk A/S.

IO Biotech is a clinical-stage biopharmaceutical company focused on developing innovative immune therapies for cancer treatment. Utilizing its unique T-win technology platform, the company creates first-in-class immune-modulating cancer vaccines that aim to activate T cells specific to immune-suppressive molecules. This approach allows for the simultaneous targeting and disruption of multiple pathways that tumors exploit to evade the immune response. IO Biotech has demonstrated a strong capability in advancing its preclinical and clinical candidates, with its two leading compounds targeting IDO and PD-L1 currently in clinical development, while several others are in the preclinical phase.

Beta Bionics is a biotechnology company focused on developing advanced solutions for diabetes management. Its flagship product, the iLet Bionic Pancreas System, is an integrated device designed to alleviate the burden of diabetes care. This system encompasses a dual-chamber infusion pump that delivers insulin and glucagon with precision and accuracy, autonomously calculating and administering doses to help patients maintain optimal blood sugar levels. The iLet has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal, and it incorporates Zealand Pharma’s dasiglucagon, which is known for its stability in a ready-to-use aqueous solution. Through these innovations, Beta Bionics aims to improve the quality of life for individuals living with diabetes.

MB2 operates in the healthcare industry that focuses on pharmaceutical businesses. It specializes in the fields of therapeutics, healthcare, and pharmaceuticals. MB2 is a U.S.-based company that was founded in 2014. The company was acquired by Novo Nordisk on August 27, 2015.

Calibrium is a privately-held biopharmaceutical company dedicated to the development of innovative drug candidates aimed at treating diabetes and related metabolic diseases. Co-founded by Fritz French, who serves as Chief Executive Officer, and Richard DiMarchi, PhD, the company's Chief Scientific Officer, Calibrium is focused on advancing its portfolio to address pressing health challenges associated with metabolic disorders.

Affimed NV is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies. With nearly two decades of expertise in innate immunity, Affimed seeks to leverage the innate immune system to enhance cancer treatment outcomes. The company specializes in discovering and advancing targeted therapies through its unique approach of using innate cell engagers, which aim to address the limitations of existing immuno-oncology therapies. In addition to its core research and development efforts, Affimed also generates revenue by providing research and development services to third parties, utilizing both its own and externally licensed intellectual property.

Osprey Pharmaceuticals USA, Inc., established in 2008 and headquartered in San Francisco, specializes in developing protein therapeutics to treat inflammatory and immune diseases. Its primary focus is on advancing a pipeline of proprietary fusion proteins called Leukocyte Population Modulators (LPMs), designed to selectively target and neutralize chemokine-activated leukocytes involved in various inflammatory conditions. The company's lead candidate, CCL2-LPM, targeting the CCR2 chemokine receptor, is currently in Phase Ib clinical trials for treating IgA nephropathy, an inflammatory kidney disease.

Xencor, Inc. is a clinical-stage biopharmaceutical company headquartered in Monrovia, California, specializing in the discovery and development of engineered monoclonal antibodies and other protein therapeutics aimed at treating severe and life-threatening diseases. The company leverages its proprietary XmAb technology platform to create a range of antibody product candidates for various conditions, including cancer and autoimmune diseases. Notable candidates in its portfolio include XmAb5871 and AIMab7195, both targeting autoimmune disorders, and several bispecific antibodies currently in clinical trials, such as XmAb14045 for acute myeloid leukemia and plamotamab for B-cell malignancies. Additionally, Xencor is advancing therapies for neuroendocrine tumors and gastrointestinal stromal tumors, as well as developing preclinical bispecific antibodies for various cancers. The company generates revenue through research and development collaborations and licensing agreements with major pharmaceutical firms. Founded in 1997, Xencor is committed to addressing unmet medical needs through innovative therapeutic solutions.

Innate Pharma S.A. is a biotechnology company based in Marseille, France, focused on discovering and developing therapeutic antibodies for oncology and inflammatory diseases. The company specializes in first-in-class immunotherapy drug candidates that target receptors and pathways controlling innate immunity. Its product pipeline includes Monalizumab, an immune checkpoint inhibitor in Phase II trials for advanced solid tumors, and Lacutamab, an anti-KIR3DL2 antibody in Phase II trials for cutaneous T-cell lymphoma. Other notable candidates include IPH5201, a CD39-targeting antibody in Phase I trials, and IPH5301, a CD73-blocking antibody in preclinical development. Innate Pharma utilizes its proprietary ANKET platform to create innovative therapies and has established licensing and collaboration agreements with major pharmaceutical companies. Founded in 1999, Innate Pharma continues to advance its mission of harnessing the innate immune system to improve cancer treatment outcomes.

Aldaph SpA manufactures, packages, and markets pharmaceutical products.

TransTech Pharma, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of human therapeutics. The company engages in translating human proteins into medicines for the treatment of various human diseases. Its products include a pipeline of molecule clinical and pre-clinical drug candidates, including antagonists, fusion proteins, activators, inhibitors, agonists, smallpox anti-virals, and thrombosis for the treatment of cardiovascular disorders, central nervous system disorders, inflammatory and infectious diseases, diabetes, obesity, and cancer. TransTech Pharma, Inc. has strategic alliances with Novo Nordisk A/S, Pfizer, Boehringer Ingelheim, Merck, Siga Technologies, and Cephalon. The company was founded in 1998 and is based in High Point, North Carolina.

Biobras is a manufacturer and distributor of medical and pharmaceutical products designed for both human and veterinary use. The company specializes in a variety of dosage forms, including ampoules, tablets, capsules, vials, ointments, powders, and suspensions. By focusing on the production of high-quality pharmaceutical preparations, Biobras aims to meet the diverse needs of the healthcare market, ensuring safe and effective options for internal and external consumption.

ZymoGenetics is a biotechnology company dedicated to the discovery, development, and early manufacturing of therapeutic proteins aimed at treating human diseases. As a fully-integrated research and development organization, it possesses a diverse array of competencies, including molecular and cellular biology, protein chemistry, and antibody generation and engineering. The company is actively involved in the clinical development and operations of its products and addresses regulatory affairs and quality control. ZymoGenetics is known for its therapeutic pipeline, which includes recothrom, a protein designed for hemostasis, underscoring its commitment to advancing innovative treatments in the biopharmaceutical sector.